Lose weight with Belviq

Lose 5 lbs per week with new FDA approved appetite suppressor Belviq with hunger, exercise or cravings. Belviq has no significant side effects is safe and effective. Lose 5 lbs per week with new FDA approved appetite suppressor Belviq with hunger, exercise or cravings. Belviq has no significant side effects is safe and effective.

The new weight loss pill Belviq (lorcaserin hydrochloride), made by Arena Pharmaceutical's company has been recently approved by the Fda. This is the first drug for long-term weight loss that has been cleared by the Food and Drug Administration in 13 years. Belviq works by activating the serotonin 2C receptor in the brain which could help you eat less by feeling full longer after small meals. When used with a combination of a balanced diet and exercise, this prescription helps individuals lose about 5% or more of their beginning weight.

Adults who contain a body mass index (BMI) of 27 or higher (overweight) are approved for Lose weight with Belviq which should be available in the first quarter of 2013. This is also for adults who are obese with a BMI of 30 or higher Approximately 36 percent of adults in America are obese, which is roughly 30 more pounds over a healthy weight. Those extra pounds increase the risk of heart disease, type-2 diabetes, stroke, many other types of cancer, sleep apnea and other debilitating and chronic diseases. There are about 42 percent of adults who are projected to be obese by the year 2030 if something isn't done to stop the trend.

There were three randomized, placebo-controlled tests that contained approximately 8,000 overweight and obese patients, with and without type-2 diabetes, treated for 52 to 104 weeks. These trials were used to evaluate the efficacy and safety of Belviq. The results show that individuals who took Belviq for at least 12 months had an average weight loss of 3% to 3.7%.

It will be mandatory for the drug's manufacturer to conduct 6 post-marketing studies, including a long-term cardiovascular outcomes trial to assess the effect of Belviq one the risk for major adverse cardiac events such as stroke and heart attack. The heart function valve of about 8,000 patients was assessed by echocardiography in the Belviq development program.